The tweet was deleted by the author.
But we saved everything 🙂.
Jonah Lupton, an investor and market commentator, said that HIMS' strengthened partnership with LLY puts the company in a strong position to be among the first to offer Retatrutide once it is approved by the FDA in 2027.
Lupton also stated that, in his opinion, Retatrutide will become the biggest selling drug of all time.
View post on X Loading...
Lupton has recently commented on notable developments in the semiconductor sector. He reported on the 12% drop in MRVL stock following rumors of an MRVL acquisition of LITE. In a separate update, he covered MRVL's agreement to acquire LITE in an all stock transaction valued at $115 billion.